Current role of radiation therapy for multiple myeloma

Frontiers in Oncology
Giampaolo TalamoJohn M Varlotto

Abstract

Radiation therapy (RT) is a treatment modality traditionally used in patients with multiple myeloma (MM), but little is known regarding the role and effectiveness of RT in the era of novel agents, i.e., immunomodulatory drugs and proteasome inhibitors. We retrospectively reviewed data from 449 consecutive MM patients seen at our institute in 2010-2012 to assess indications for RT as well as its effectiveness. Pain response was scored similarly to RTOG 0631 and used the Numerical Rating Pain Scale. Among 442 evaluable patients, 149 (34%) patients and 262 sites received RT. The most common indication for RT was palliation of bone pain (n = 109, 42%), followed by prevention/treatment of pathological fractures (n = 73, 28%), spinal cord compression (n = 26, 10%), and involvement of vital organs/extramedullary disease (n = 25, 10%). Of the 55 patients evaluable for pain relief, complete and partial responses were obtained in 76.4 and 7.2%, respectively. Prior RT did not significantly decrease the median number of peripheral blood stem cells collected for autologous transplant, even when prior RT was given to both the spine and pelvis. Inadequacy of stem cell collection for autologous stem cell transplant (ASCT) was not significantly...Continue Reading

References

Feb 1, 1991·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·I A AdamietzK Renner
Aug 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A R BelchB Zee
Dec 1, 1988·International Journal of Radiation Oncology, Biology, Physics·A Bosch, Z Frias
May 8, 1971·British Medical Journal·D E Bergsagel
Dec 1, 1984·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J DeaconG G Steel
May 1, 1982·British Journal of Cancer·T ShimizuH Mizoguchi
May 1, 1981·International Journal of Radiation Oncology, Biology, Physics·B Fertil, E P Malaise
Nov 1, 1995·International Journal of Radiation Oncology, Biology, Physics·W C DeweyR E Meyn
Apr 2, 1993·International Journal of Radiation Oncology, Biology, Physics·B R LeighD S Shimm
Feb 18, 1999·Current Opinion in Chemical Biology·E C JonathanW G McKenna
Jul 25, 2003·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Jae-Lyun LeeCheolwon Suh
Jan 1, 1931·Annals of Surgery·W B Coley
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
May 13, 2008·Cancer Metastasis Reviews·Marcel Verheij
Feb 3, 2009·Haematologica·Joan Bladé, Laura Rosiñol
Jul 7, 2010·The British Journal of Radiology·J F Fowler
Dec 16, 2010·Clinical Lymphoma, Myeloma & Leukemia·Giampaolo TalamoElliot Epner
Feb 22, 2011·Annals of Hematology·Sonja KrauseDirk Neuhof

❮ Previous
Next ❯

Citations

Apr 23, 2016·Radiation Oncology Journal·Jeong Won Lee, Jeong Eun Lee
Oct 30, 2016·Journal of Neurosurgery. Spine·Jacob A MillerLilyana Angelov
Mar 1, 2017·Current Hematologic Malignancy Reports·Nicholas BinghamAndrew Spencer
Sep 2, 2017·Current Osteoporosis Reports·Cristina PanaroniNoopur S Raje
Feb 28, 2019·Blood Cancer Journal·Chris PlummerMaría-Victoria Mateos
Jul 9, 2020·Frontiers in Immunology·Wassilis S C BruinsNiels W C J van de Donk
Jan 14, 2021·Annals of Hematology·Sikander AilawadhiTaimur Sher
Jan 1, 2021·Medicina·Liliana BelgioiaRenzo Corvò
Mar 12, 2021·Current Hematologic Malignancy Reports·Guillermo J Ruiz-Argüelles, David Gómez-Almaguer
Nov 6, 2021·Expert Review of Hematology·Massimiliano CamilliAntonella Lombardo

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
ISS

Software Mentioned

SAS

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Journal of the National Comprehensive Cancer Network : JNCCN
Matthew Mei, George Somlo
Expert Opinion on Biological Therapy
Massimo Martino, Fortunato Morabito
Current Hematologic Malignancy Reports
Isabel Ruth PreeshagulTomer M Mark
© 2022 Meta ULC. All rights reserved